Novel Therapeutic Combination Targets the Growth of Letrozole-Resistant Breast Cancer through Decreased Cyclin B1

As breast cancer cells transition from letrozole-sensitive to letrozole-resistant, they over-express epidermal growth factor receptor (EGFR), mitogen-activated protein kinase (MAPK), and human epidermal growth factor receptor 2 (HER2) while acquiring enhanced motility and epithelial-to-mesenchymal t...

Descripción completa

Detalles Bibliográficos
Autores principales: Patel, Jankiben R., Banjara, Bipika, Ohemeng, Afia, Davidson, A. Michael, Boué, Stephen M., Burow, Matthew E., Tilghman, Syreeta L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10097176/
https://www.ncbi.nlm.nih.gov/pubmed/37049472
http://dx.doi.org/10.3390/nu15071632

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10097176/
https://www.ncbi.nlm.nih.gov/pubmed/37049472
http://dx.doi.org/10.3390/nu15071632

Ejemplares similares